Take orally, once daily in the evening, with or without food. For asthma, take in the evening. For allergic rhinitis, timing may be adjusted to suit patient needs. For exercise-induced bronchoconstriction, take at least 2 hours before exercise.

Montelukast selectively antagonizes the CysLT1 receptor, blocking the action of leukotriene D4 (LTD4), a potent inflammatory mediator released from mast cells and eosinophils. This inhibition helps to reduce bronchoconstriction and inflammatory responses associated with asthma and allergic rhinitis.

• •Known hypersensitivity to montelukast or any component of the tablet.

Store below 30°C in a dry place, away from light and moisture. Keep out of reach of children.

Symptoms of overdose include abdominal pain, somnolence, thirst, headache, vomiting, and psychomotor hyperactivity. Treatment is symptomatic and supportive.

Pregnancy Category B. Studies in animals have shown no evidence of harm to the fetus, but there are no adequate and well-controlled studies in pregnant women. Use only if clearly needed. Montelukast is excreted in breast milk; caution should be exercised when administered to a nursing woman.